BUFFALO, N.Y. -- Buffalo medical researchers led by a team from the University at Buffalo Department of Neurosurgery, will embark on a landmark prospective randomized double-blinded study to test the safety and efficacy of interventional endovascular therapy -- dubbed "liberation treatment" -- on the symptoms and progression of Multiple Sclerosis (MS).
Recent research has strongly associated chronic cerebrospinal venous insufficiency (CCSVI) with MS.
In a series of original studies, Paolo Zamboni MD, of the University of Ferrara, Italy, found blockage of major venous outflow from the brain and spinal cord in patients with MS. Researchers from many institutions, including the University at Buffalo, have confirmed the association.
It is hypothesized that the narrowing in the large veins in the neck and chest might cause improper drainage of blood from the brain, resulting in eventual injury to brain tissue. It is thought that angioplasty -- treatment commonly used by cardiologists and other endovascular surgeons to treat atherosclerosis -- may remedy the blockages.
Zamboni has conducted preliminary studies that suggest the efficacy of venous angioplasty "liberation procedure" -- in the amelioration of MS symptoms.
Now, researchers at the University at Buffalo will launch PREMiSe (Prospective Randomized Endovascular therapy in Multiple Sclerosis), a study to determine if endovascular intervention via balloon angioplasty to correct the blockages improves MS symptoms or progression.
PREMiSe is believed to be the first prospective randomized double-blinded study of balloon angioplasty for MS being performed with Institutional Review Board approval in a rigorous fashion in the US with significant safeguards in place to ensure careful determination of risks and benefits.
The study is led by principal investigator Adnan Siddiqui, MD, assistant professor of Neurosurgery, UB School of Medicine and Biomedical Sci
|Contact: Paul Dressel|
University at Buffalo